A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors

被引：0
|
作者：
Pelster, Meredith
Torre, Marcio
Kannan, Geoffrey Sumithran
Gargano, Michele Anne
Mattson, Paulette
Rathmann, Blaine
Bose, Nandita
Iglesias, Jose Luis
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] HiberCell Inc, New York, NY USA
[3] Labcorp, Burlington, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3179
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An open-label, phase 1a/b study of AB248, a CD8+selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
    Buchbinder, Elizabeth I.
    Spigel, David R.
    Albany, Costantine
    Chisamore, Michael
    Moynihan, Kelly D.
    Liu, Xiaohan
    DelNagro, Christopher
    Axt, Matt
    Pirzkall, Andrea
    CANCER RESEARCH, 2023, 83 (08)
  • [32] IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04)
    Song, Zhengbo
    Tong, Xu
    Zhang, Yan
    Zhu, Hui
    Zhao, Yanqiu
    Yu, Xiaoqing
    Ai, Xinghao
    Zong, Zhenzhen
    Zhao, Xiwen
    Gao, Siman
    Lu, Qiying
    Tian, Wenzhi
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] DELTA-2: A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF ITIL-168, AN AUTOLOGOUS TUMORINFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Yeku, Oladapo
    Olson, Daniel
    Ward, Jeffrey
    Patel, Sandip
    Aycock, Jeff
    Donahue, Amber
    Jiang, Yizhou
    Le Gall, John
    Roberts, Zachary
    Alvarez-Rodriguez, Ruben
    Seng, Judy
    Shen, Tong
    Kothari, Nishi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A813 - A813
  • [34] A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
    Janku, Filip
    Kauh, John S.
    Tucci, Christopher
    Yang, Zhao
    Kania, Marek K.
    Alese, Olatunji B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
    Hansen, Aaron Richard
    Zhang, Alison Yan
    Boni, Valentina
    Mantia, Charlene
    Yu, Evan Y.
    Weickhardt, Andrew James
    Robert, Marie
    Gupta, Shilpa
    Morales-Barrera, Rafael
    Hoimes, Christopher J.
    Berlin, Jordan
    Iyer, Gopa
    Millward, Michael
    Lihou, Christine Francis
    Loriot, Yohan
    Pouessel, Damien
    Mittal, Kriti
    Hill, Andrew Graham
    Racca, Fabricio
    Tran, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS904 - TPS904
  • [36] A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)
    Zhang, A.
    Boni, V.
    Hanson, A.
    Mantia, C.
    Weickhardt, A.
    Yu, E.
    Gupta, S.
    Robert, M.
    Iyer, G.
    Millward, M.
    Morales-Barrera, R.
    Hoimes, C.
    Berlin, J.
    Mittal, K.
    Hill, A.
    Racca, F.
    Pouessel, D.
    Lihou, C.
    Tran, B.
    Loriot, Y.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S15 - S16
  • [37] A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors
    Rivera, Ismael Rodriguez
    Shen, Lin
    Kummar, Shivaani
    Barve, Minal
    Germa, Caroline
    Qi, Chuan
    Chen, Lei
    Milata, Jenny
    Yao, Jenny
    Shen, Li
    Zhu, Xuelian
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
    Lim, Emerson A.
    Bendell, Johanna C.
    Falchook, Gerald S.
    Bauer, Todd M.
    Drake, Charles G.
    Choe, Jennifer H.
    George, Daniel J.
    Karlix, Janet L.
    Ulahannan, Susanna
    Sachsenmeier, Kris F.
    Russell, Deanna L.
    Moorthy, Ganesh
    Sidders, Ben S.
    Pilling, Elizabeth A.
    Chen, Huifang
    Hattersley, Maureen M.
    Das, Mayuk
    Kumar, Rakes
    Pouliot, Gayle P.
    Patel, Manish R.
    CLINICAL CANCER RESEARCH, 2022, 28 (22) : 4871 - 4884
  • [39] Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors
    Janku, F.
    Abdul-Karim, R.
    Azad, A.
    Bendell, J.
    Gan, H.
    Sen, S.
    Tan, T.
    Wang, J.
    Marina, N.
    Baker, L.
    Ma, L.
    Mooney, J.
    Luo, D.
    Leveque, J.
    Milla, M.
    Meniawy, T.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S11 - S11
  • [40] A phase II, open-label, multicenter, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors (ARTIST)
    Aghajanian, Carol
    Washington, Christina
    Moore, Kathleen
    Krivak, Thomas
    Mathews, Cara
    Philip, Tony
    Konecny, Gottfried
    Fleming, Gini
    Martin, Niall
    Smith, Graeme
    Harrop, Bryony
    Millward, Helen
    Skelton, Samantha
    Little, Nicola
    Headley, Desiree
    Smith, Ian
    Konstantinopoulos, Panagiotis
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S296 - S297
12345